UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients
NCT00113919
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
14
Enrollment
OTHER
Sponsor class
Stopped
Due to poor accrual
Conditions
Multiple Myeloma
Interventions
DRUG:
Busulfan
Sponsor
University of Arkansas